Objectif Inheriting one mutant copy of the BRCA1 or BRCA2 gene is associated with a significant increased risk for developing aggressive and difficult to treat breast cancer, the most common cancer type in women worldwide. Despite previous efforts to recapitulate tumorigenesis with the use of mouse models and cancer cell lines, the exact mechanisms that underlie BRCA1 or BRCA2-dependent tumor development remain unclear. Recent advances in stem cell culturing have enabled long-term expansion of in vitro human breast organoids or ‘mini-breasts’. In a novel approach, this state-of-the-art culture technology will be used together with CRISPR/Cas9-mediated gene-editing and human-in-mouse xenografts to prospectively recapitulate early breast cancer development. Results of the study will generate novel fundamental insight into the development of breast cancer, support the development of personalized medicine using laboratory models, and aspires to identify novel breast cancer biomarkers and treatment strategies.The expertise of the laboratory of H. Clevers, who pioneered the organoid methodology and works at the top of the field of stem cell biology, will be combined with the expertise of the research group of J. Visvader and G. Lindeman, world leaders in the field of breast cancer research and experts in the methodology of mammary xenotransplantation. This unique setting forms an excellent envorinment for my postdoctoral research training, allows extensive knowledge exchange and provides opportunities for novel research lines and collaborations. Champ scientifique medical and health sciencesmedical biotechnologygenetic engineeringgene therapymedical and health sciencesmedical biotechnologycells technologiesstem cellsmedical and health sciencesclinical medicineoncologybreast cancermedical and health scienceshealth sciencespersonalized medicinemedical and health sciencesclinical medicinetransplantation Programme(s) H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions Main Programme H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility Thème(s) MSCA-IF-2015-GF - Marie Skłodowska-Curie Individual Fellowships (IF-GF) Appel à propositions H2020-MSCA-IF-2015 Voir d’autres projets de cet appel Régime de financement MSCA-IF-GF - Global Fellowships Coordinateur KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN - KNAW Contribution nette de l'UE € 207 584,40 Adresse KLOVENIERSBURGWAL 29 HET TRIPPENHUIS 1011 JV AMSTERDAM Pays-Bas Voir sur la carte Région West-Nederland Noord-Holland Groot-Amsterdam Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 207 584,40 Partenaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire Partenaire Les organisations partenaires contribuent à la mise en œuvre de l’action, mais ne signent pas la convention de subvention. THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH PUBLIC COMPANYLIMITED BY GUARANTEE Australie Contribution nette de l'UE € 0,00 Adresse ROYAL PARADE 1G 3050 Parkville Voir sur la carte Type d’activité Research Organisations Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 124 785,00